OncoMatch/Clinical Trials/NCT06704152
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Is NCT06704152 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including SOC + BSB-1001 Dose Escalation Cohort and SOC+BSB-1001 Expansion Dose for aml, adult recurrent.
Treatment: SOC + BSB-1001 Dose Escalation Cohort · SOC+BSB-1001 Expansion Dose — The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: HLA-A A*02:01 positive
HLA-A*02:01
Required: HA-1 positive (either H/H or H/R)
HA-1 positive (either H/H or H/R)
Allowed: TP53 mutation
TP53 mutation
Prior therapy
Must have received:
AML diagnosed which has been treated with at least two lines of therapy
Must have received:
MDS after at least one line of therapy, which includes hypomethylating agent(s)
Cannot have received: allogeneic stem cell transplantation
Prior history of allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplantation
Exception: within 1 year prior to the planned dosing of BSB-1001 (day 0)
Prior history of autologous stem cell transplantation within 1 year prior to the planned dosing of BSB-1001 (day 0)
Cannot have received: CAR-T cell therapy
Exception: patients with ALL previously treated with an autologous CAR-T product
Previous genetically engineered chimeric antigen receptor T Cell therapy (CAR-T), approved or investigational, within 2 years of screening, with the exception of patients with ALL previously treated with an autologous CAR-T product
Cannot have received: investigational agent
Exception: within 5 half-lives of the planned dosing of BSB-1001 (day 0)
Treatment with other investigational agents within 5 half-lives of the planned dosing of BSB-1001 (day 0)
Cannot have received: checkpoint inhibitor
Exception: within 3 months of transplantation
History of treatment with checkpoint inhibitor therapy within 3 months of transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- Moffitt Cancer Center · Tampa, Florida
- University of Michigan · Ann Arbor, Michigan
- University of Minnesota · Minneapolis, Minnesota
- Washington University at St Louis · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify